Related references
Note: Only part of the references are listed.Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
Warren Fiskus et al.
BLOOD (2009)
A monoclonal gammopathy precedes multiple myeloma in most patients
Brendan M. Weiss et al.
BLOOD (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
Clinical Studies of Histone Deacetylase Inhibitors
H. Miles Prince et al.
CLINICAL CANCER RESEARCH (2009)
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
Tina Branscombe Miranda et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
Gijs van Haaften et al.
NATURE GENETICS (2009)
Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma
Marina Tshuikina et al.
EXPERIMENTAL HEMATOLOGY (2008)
Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells
Qun Zhou et al.
MOLECULAR CANCER RESEARCH (2008)
Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors
Fabio Mohn et al.
MOLECULAR CELL (2008)
A model for transmission of the H3K27me3 epigenetic mark
Klaus H. Hansen et al.
NATURE CELL BIOLOGY (2008)
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation
Yutaka Kondo et al.
NATURE GENETICS (2008)
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors
Ittai Ben-Porath et al.
NATURE GENETICS (2008)
Mechanisms controlling cell cycle exit upon terminal differentiation
Laura A. Buttitta et al.
CURRENT OPINION IN CELL BIOLOGY (2007)
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome
Jindan Yu et al.
CANCER RESEARCH (2007)
A role for EZH2 in silencing of IFN-γ inducible MHC2TA transcription in uveal melanoma
Tjadine M. Holling et al.
JOURNAL OF IMMUNOLOGY (2007)
Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma
Jonathan J. Keats et al.
CANCER CELL (2007)
Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma
Christina M. Annunziata et al.
CANCER CELL (2007)
Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells
Jing Tan et al.
GENES & DEVELOPMENT (2007)
A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1
John D. Shaughnessy et al.
BLOOD (2007)
The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells
Adrian P. Bracken et al.
GENES & DEVELOPMENT (2007)
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
Fenghuang Zhan et al.
BLOOD (2007)
Epigenetic stem cell signature in cancer
Martin Widschwendter et al.
NATURE GENETICS (2007)
Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer
Yeshayahu Schlesinger et al.
NATURE GENETICS (2007)
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing
Joyce E. Ohm et al.
NATURE GENETICS (2007)
Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma
Luca Agnelli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling
Wee J. Chng et al.
CANCER RESEARCH (2007)
Polycomb silencing mechanisms and the management of genomic programmes
Yuri B. Schwartz et al.
NATURE REVIEWS GENETICS (2007)
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells
Warren Fiskus et al.
MOLECULAR CANCER THERAPEUTICS (2006)
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
Patricia Maiso et al.
CANCER RESEARCH (2006)
Polycomb complexes repress developmental regulators in murine embryonic stem cells
LA Boyer et al.
NATURE (2006)
Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions
AP Bracken et al.
GENES & DEVELOPMENT (2006)
The Polycomb group protein EZH2 directly controls DNA methylation
E Viré et al.
NATURE (2006)
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
AH Bild et al.
NATURE (2006)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype
PA Croonquist et al.
ONCOGENE (2005)
Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma
M Mattioli et al.
ONCOGENE (2005)
CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
S Trudel et al.
BLOOD (2005)
Characterization of clonogenic multiple myeloma cells
W Matsui et al.
BLOOD (2004)
Stem colls and cancer: The polycomb connection
ME Valk-Lingbeek et al.
CELL (2004)
Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27
A Kirmizis et al.
GENES & DEVELOPMENT (2004)
ONCOMINE: A cancer microarray database and integrated data-mining platform
DR Rhodes et al.
NEOPLASIA (2004)
Multiple myeloma biology: lessons from the 5TMM models
K Vanderkerken et al.
IMMUNOLOGICAL REVIEWS (2003)
Role of histone H3 lysine 27 methylation in polycomb-group silencing
R Cao et al.
SCIENCE (2002)
A long-term study of prognosis in monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
FH Zhan et al.
BLOOD (2002)
Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells
N Ghosh et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
